(Reuters) - The Cambridge, Massachusetts-based company said the
decision to hold up development of valopicitabine in the United
States was based on the "overall risk/benefit profile observed
to date in clinical testing."
"We are disappointed with the perspective on the program, and are working
with Novartis to evaluate our options for valopicitabine,"
Idenix Chief Executive Jean-Pierre Sommadossi said in a
statement.
Read more at Reuters.com Government Filings News
decision to hold up development of valopicitabine in the United
States was based on the "overall risk/benefit profile observed
to date in clinical testing."
"We are disappointed with the perspective on the program, and are working
with Novartis to evaluate our options for valopicitabine,"
Idenix Chief Executive Jean-Pierre Sommadossi said in a
statement.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment